Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
11.01
+0.21 (1.94%)
May 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.60 - 11.52
52 week 6.51 - 16.49
Open 10.82
Vol / Avg. 289,180.00/227,022.00
Mkt cap 326.23M
P/E     -
Div/yield     -
EPS -2.89
Shares 29.53M
Beta 0.98
Inst. own 95%
May 14, 2015
Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference - 2:20PM EDT - Add to calendar
May 6, 2015
Q1 2015 Heron Therapeutics Inc Earnings Release (Estimated) Add to calendar
Mar 13, 2015
Q4 2014 Heron Therapeutics Inc Earnings Release
Mar 9, 2015
Heron Therapeutics Inc at ROTH Conference
Mar 4, 2015
Heron Therapeutics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -97.92% -100.08%
Return on average equity -114.84% -115.70%
Employees 59 -
CDP Score - -

Address

123 SAGINAW DRIVE
REDWOOD CITY, CA 94063
United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heron Therapeutics, Inc. is a biotechnology company. The Company is using its proprietary technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Heron�s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The Company�s product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Robert H. Rosen President, Director
Age: 59
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Esme C. Smith Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 54
Bio & Compensation  - Reuters
Craig A. Johnson Independent Director
Age: 53
Bio & Compensation  - Reuters
Kimberly J. Manhard Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Poyhonen Independent Director
Age: 55
Bio & Compensation  - Reuters